help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on May 6, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-2414
This Article
Right arrow Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Nielsen, C.
Right arrow Articles by Jørgensen, J. O. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nielsen, C.
Right arrow Articles by Jørgensen, J. O. L.
Related Collections
Right arrow Metabolism

Submitted on October 30, 2007
Accepted on April 25, 2008

Growth hormone signaling in vivo in human muscle and adipose tissue: Impact of insulin, substrate background and growth hormone receptor blockade

Charlotte Nielsen*, Lars C. Gormsen, Niels Jessen, Steen Bønløkke Pedersen, Niels Møller, Sten Lund, and Jens Otto L. Jørgensen

Medical Dept. M (Endocrinology and Diabetes) Aarhus University Hospital, Medical Dept. C, Aarhus University Hospital

* To whom correspondence should be addressed. E-mail: lolle{at}sol.dk.

Context: GH induces insulin resistance in muscle and fat and in vitro data indicate that this may involve crosstalk between the signaling pathways of the two hormones.

Objective: To investigate GH and insulin signaling in vivo in human muscle and fat tissue in response to GH, GH receptor blockade and insulin stimulation.

Design: 2 randomized cross-over studies.

Participants: 16 healthy males.

Intervention: Administration of GH as a bolus (n=8) and constant infusion (n=8). The bolus study included 3 arms: 1) control (saline), 2) GH (0.5 mg i.v.), and 3) GH blockade (pegvisomant 30 mg s.c.) each combined with a hyperinsulinemic glucose clamp. The infusion study included 2 arms: 1) GH infusion (45 ng|b1kg-1|b1min-1, 51/2 h) and 2) saline infusion (51/2 h) combined with a hyperinsulinemic glucose clamp during the final 21/2 h.

Main Outcome Measures: Muscle and fat biopsies were subjected to western blotting for expression of Stat5/p-Stat5, Akt/p-Akt and ERK 1/2/p-ERK 1/2 and to real-time RT-PCR for expression of SOCS1–3 and IGF-I mRNA.

Results: GH significantly reduced insulin sensitivity. The GH bolus as well as GH infusion induced phosphorylation of Stat5 in muscle and fat, and SOCS3 and IGF-I mRNA expressions increased after GH infusion. Hyperinsulinemia induced Akt phosphorylation in both tissues, irrespective of GH status. In muscle ERK 1/2 phosphorylation was increased by insulin, but insulin per se did not induce phosphorylation of Stat5.

Conclusions: GH exposure associated with insulin resistance acutely translates into GH receptor signaling in human muscle and fat without evidence of crosstalk with insulin signaling pathways. The molecular mechanisms subserving GH-induced insulin resistance in humans remain unclarified.


Key words: Growth hormone • insulin • signal transduction







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society